Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 6/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14758954 | 0.89 | FFAR1 (0.70) | MRGPRX4FFAR1PPARAHIF1ANPC1 | |
| SCHEMBL12581587 | 0.89 | MRGPRX4 (0.73) | MRGPRX4FFAR1PPARAHIF1ANPC1 | |
| SCHEMBL11248670 | 0.87 | HIF1A (0.58) | MRGPRX4HIF1AHDAC8HDAC6 | |
| SCHEMBL2188996 | 0.87 | PPARA (0.79) | MRGPRX4FFAR1PPARANPC1RAB9A | |
| SCHEMBL2185809 | 0.86 | FFAR1 (0.70) | MRGPRX4FFAR1PPARAHIF1ANPC1 | |
| SCHEMBL10055040 | 0.84 | FFAR1 (0.68) | MRGPRX4FFAR1PPARAHIF1AAKR1C3 | |
| SCHEMBL6840198 | 0.84 | PPARA (0.60) | MRGPRX4FFAR1PPARANPC1RAB9A | |
| SCHEMBL27488835 | 0.84 | FFAR1 (0.67) | MRGPRX4FFAR1PPARAHIF1ANPC1 | |
| SCHEMBL1287947 | 0.83 | HIF1A (0.83) | MRGPRX4FFAR1HIF1ANPC1RAB9A | |
| SCHEMBL6700054 | 0.82 | CHRM2 (0.55) | KDM4EHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | MRGPRX4 2781/4885FFAR1 3064/4885PPARA 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.